Parameters | Pembrolizumab plus EP | EP |
---|
LYs | 1.83 | 1.51 |
QALYs | 1.07 | 0.89 |
Total cost $ | 130,692 | 17,067 |
ICER $/LY a | 346,818 | - |
ICER $/QALY b | 647,509 | - |
WTP $/QALY | 150,000 | - |
- EP: Etoposide and Platinum; ICER: incremental cost-effectiveness ratio; LY: life-year; QALY: quality-adjusted life-year; WTP: willingness-to-pay
- a Compared to EP ($/LY)
- b Compared to EP ($/QALY)